nach oben

Current Oncology Reports

Erschienen in:

01.10.2017 | Evolving Therapies (R Bukowski, Section Editor)

Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics

verfasst von: Jonathan L. Messerschmidt, Prianka Bhattacharya, Gerald L. Messerschmidt

Erschienen in: Current Oncology Reports | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The knowledge base of malignant cell growth and resulting targets is rapidly increasing every day. Clonal theory is essential to understand the changes required for a cell to become malignant. These changes are then clues to therapeutic intervention strategies. Immune system optimization is a critical piece to find, recognize, and eliminate all cancer cells from the host. Only by administering (1) multiple therapies that counteract the cancer cell’s mutational and externally induced survival traits and (2) by augmenting the immune system to combat immune suppression processes and by enhancing specific tumor trait recognition can cancer begin to be treated with a truly targeted focus.

Recent findings

Since the sequencing of the human genome during the 1990s, steady progress in understanding genetic alterations and gene product functions are being unraveled. In cancer, this is proceeding very fast and demonstrates that genetic mutations occur very rapidly to allow for selection of survival traits within various cancer clones. Hundreds of mutations have been identified in single individual cancers, but spread across many clones in the patient’s body. Precision oncology will require accurate measurement of these cancer survival-benefiting mutations to develop strategies for effective therapy. Inhibiting these cellular mechanisms is a first step, but these malignant cells need to be eliminated by the host’s mechanisms, which we are learning to direct more specifically.

Summary

Cancer is one of the most complicated cellular aberrations humans have encountered. Rapidly developing significant survival traits require prompt, repeated, and total body measurements of these attributes to effectively develop multi-agent treatment of the individual’s malignancy. Focused drug development to inhibit these beneficial mutations is critical to slowing cancer cell growth and, perhaps, triggering apoptosis. In many cases, activation and targeting of the immune system to kill the remaining malignant cells is essential to a cure.

• Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–8. This is the landmark paper that describes the clonal theory of cancer. CrossRefPubMed

• Ludmil BA, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. This paper describes the whole genome sequencing of ~7,000 tumor samples and finding701 mutations on average. CrossRef

• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. In: Arnold J. Levine and David Lane, editors, additional perspectives on the p53 family. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. doi:10.1101/cshperspect.a001008. This chapter presents the location of p53 mutations in coding, non-coding and salient regions of the genes, including promotors. This suggests that malignancy could result for mutations in any portion of a gene sequence, not just the protein coded area. CrossRefPubMedPubMedCentral

• Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924–35. This review builds on the “evolutionary” aspects of cancer development. CrossRefPubMed

• Pepper JW, Findlay S, Kassen R, Spencer SL, Maley CC. Cancer research meets evolutionary biology. Evol Appl. 2009;2(1):62–70. This review builds on the “evolutionary” aspects of cancer development. CrossRefPubMedPubMedCentral

• Messerschmidt JL, Pendergast GC, Messerschmidt GL. How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: helping nonimmunologists decipher recent advances. Oncologist. 2016;21:1–11. This review builds describes normal and abnormal immune system function and coins the term Darwinian “revolution”. CrossRef

• Greaves M, editor. Cancer: the evolutionary legacy. New York: Oxford University Press; 2000. This chapter presents Darwinian evolution for cancer through random mutations and sets the stage for the clonal theory acceptance as truth.

• Schreiber RD, Old LJ, Smyth ML. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70. The landmark paper describes the 3 major immune actions following cancer formation leading to death, equilibrium and immune escape. CrossRefPubMed

Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813–24.CrossRefPubMed

10.

Tan M, Quintal L. Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. J Clin Pharm Ther. 2015;40(5):504–7.CrossRef

11.

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentral

12.

Hematology/Oncology (Cancer) Approvals & Safety Notifications (2017). Available at: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm.

13.

Hematology/Oncology (Cancer) Approvals & Safety Notifications (2013-2016). Available at: http://wayback.archive-it.org/7993/20170111074854/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/default.htm.

14.

Hematology/Oncology (Cancer) Approvals & Safety Notifications (2011). Available at: http://wayback.archive-it.org/7993/20170111231727/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381453.htm.

15.

Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B, et al. Carcinogen-specific induction of genetic instability. Proc Natl Acad Sci U S A. 2001;98(10):5770–5.CrossRefPubMedPubMedCentral

16.

Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol. 1999;9(12):M57–60.CrossRefPubMed

17.

Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer. 2005;5(11):867–75.CrossRefPubMed

18.

Siegmund KD, Marjoram P, Woo Y-JJ, Tavaré S, Shibata D. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci U S A. 2009;106(12):4828–33.CrossRefPubMedPubMedCentral

19.

• Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306–13. The paper describes the data supporting the clonal theory of Newall and forms the basis of today’s understanding of the cancer clonal theory. CrossRefPubMedPubMedCentral

20.

http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age#heading-Zero. Accessed 10 May 2017.

21.

Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9(4):302–12.CrossRefPubMed

22.

Tubiana M, Malaise EP, Chavaudra N. The relationship between growth rate, labelling index and histological type of human solid tumours. Eur J Cancer. 1973;9(4):305–12.CrossRefPubMed

23.

Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011;469(7330):356–61.CrossRefPubMed

24.

Sawyers CL. Shifting paradigms: the seeds of oncogene addiction. Nat Med. 2009;15(10):1158–61.CrossRefPubMed

25.

Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319–25.CrossRefPubMed

26.

Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69–82.CrossRefPubMed

27.

Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69(11):4894–903.CrossRefPubMedPubMedCentral

28.

• Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332–6. The paper describes for the first time the clonagenic theory in myeloma cell as reality. CrossRefPubMed

29.

Calame KL. Plasma cells: finding new light at the end of b cell development. Nat Immunol. 2001;2(12):1103–8.CrossRefPubMed

30.

• Tang M, Zhao R, van de Velde H, et al. Myeloma cell dynamics in response to treatment supports a model of hierarchical differentiation and clonal evolution. Clin Cancer Res. 2016;22(16):4206–14. The paper describes that chemotherapy can “select” for prior mutated resistant (passenger) changes that become important when selections pressures are applied. CrossRefPubMedPubMedCentral

31.

Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98.CrossRefPubMed

32.

San Miguel J, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMed

33.

Salmon SE, Smith BA. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest. 1970;49(6):1114–21.CrossRefPubMedPubMedCentral

34.

• Burger JA, Landau DA, Amaro TW, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. The paper describes/confirms that chemotherapy can “select” for prior mutated resistant (passenger) changes that become important when selections pressures are applied. CrossRefPubMedPubMedCentral

35.

Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–80.CrossRefPubMedPubMedCentral

36.

Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.CrossRefPubMedPubMedCentral

37.

Woyach JA, Furman RR, Liu T-MM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–94.CrossRefPubMedPubMedCentral

38.

Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med. 2014;370(24):2352–4.CrossRefPubMedPubMedCentral

39.

•• Braxton DR, Zhang R, Morrissette JD, Loaiza-Bonilla A, Furth EE. Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic sub-groups with differing patterns of genetic evolution. Int J Cancer. 2016;139(7):1546–56. The paper describes differing patterns can select for prior mutated resistant changes that become important when selections pressures are applied. CrossRefPubMed

40.

Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26–38.CrossRefPubMedPubMedCentral

41.

Camacho E, Hernández L, Hernández S, et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood. 2002;99(1):238–44.CrossRefPubMed

42.

Wu C, de Miranda NF, Chen L, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016;7(25):38180–90.CrossRefPubMedPubMedCentral

43.

Pelosi G, Pellegrinelli A, Fabbri A, et al. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016;488(6):651–62.CrossRef

44.

Hardiman KM, Ulintz PJ, Kuick RD, et al. Intra-tumor genetic heterogeneity in rectal cancer. Lab Investig. 2016;96(1):4–15.CrossRefPubMed

45.

Campos B, Olsen LR, Urup T, Poulsen HS. A comprehensive profile of recurrent glioblastoma. Oncogene. 2016;35:5819–25. doi:10.1038/onc.2016.85.CrossRefPubMed

46.

Tatematsu T, Sasaki H, Shimizu S. Intra-tumor heterogeneity of BRAF V600E mutation in lung adenocarcinomas. Exp Ther Med. 2015;9(5):1719–22.CrossRefPubMedPubMedCentral

47.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.CrossRefPubMedPubMedCentral

48.

• Kataoka K, Shiraishi Y, Takeda Y. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature. 2016;534:402–6. The paper describes genomic changes that select resistant clones via PD-L1 expression. CrossRefPubMed

49.

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–95.PubMedPubMedCentral

50.

Nishimura H, Agata Y, Kawasaki A, et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol. 1996;8:773–80.CrossRefPubMed

51.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.CrossRefPubMed

52.

Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538–45.CrossRefPubMed

53.

Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding. Eur J Immunol. 2007;37(9):2405–10.CrossRefPubMed

54.

Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–53.CrossRefPubMedPubMedCentral

55.

Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002;32:666–9.CrossRefPubMed

56.

Dong H, Strome SE, Matteson EL, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111:363–70.CrossRefPubMedPubMedCentral

57.

Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63:6501–5.PubMed

58.

Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109:1499–505.CrossRefPubMed

59.

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on nonsmall cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.CrossRefPubMed

60.

Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151–7.CrossRefPubMed

61.

Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174–9.CrossRefPubMedPubMedCentral

62.

Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–62.CrossRefPubMedPubMedCentral

63.

Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2006;30:802–10.CrossRefPubMedPubMedCentral

64.

Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110:296–304.CrossRefPubMed

65.

Chemnitz JM, Eggle D, Driesen J, et al. RNA-fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4⁺ T cells in Hodgkin’s lymphoma. Blood. 2007;110:3226–33.CrossRefPubMed

66.

Shimauchi T, Kabashima K, Nakashima D, et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4⁺ T-cells in adult T-cell leukemia/lymphoma. Int J Cancer. 2007;121:2585–90.CrossRefPubMed

67.

Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133–44.CrossRefPubMed

68.

Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol. 2005;174:3408–15.CrossRefPubMed

69.

Hori J, Wang M, Miyashita M, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;2006(177):5928–35.CrossRef

70.

Okazaki T, Honjo T. PD-1 and PD-1 ligands from discovery to clinical application. Int Immunnol. 2007;19:813–24.CrossRef

71.

Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1(8):1223–5.CrossRefPubMedPubMedCentral

72.

Finger EB, Bluestone JA. When ligand becomes receptor—tolerance via B7 signaling on DCs. Nat Immunol. 2002;3:1056–7.CrossRefPubMed

73.

Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTAL-4-Fc in human CD4⁺ T cells. Blood. 2005;105:1574–81.CrossRefPubMed

74.

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.CrossRefPubMed

75.

Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101:151–5.CrossRefPubMed

76.

Uyttenhove C, Pilotte L, Théate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.CrossRefPubMed

77.

Nishimura H, Honjo T, Minato N. Facilitation of beta selection and modification of positive selection in the thymus of PD-1 deficient mice. J Exp Med. 2000;191:891–8.CrossRefPubMedPubMedCentral

78.

Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance and function of induced regulatory T cells. J Exp Med. 2009;206:3015–29.CrossRefPubMedPubMedCentral

79.

Haxhinasto S, Mathis D, Benoist C. The AKT-m-TOR axis regulates de novo differentiation of CD4⁺ Foxp3⁺ cells. J Exp Med. 2008;205:565–74.CrossRefPubMedPubMedCentral

80.

Sauer S, Bruno L, Hertweck A, et al. T cell receptor signally controls Foxp3, AKT, and mTOR. Proc Natl Acad Sci U S A. 2008;105:7797–802.CrossRefPubMedPubMedCentral

81.

• Terme M, Ulrich E, Aymeric I, et al. IL-18 induces PD-1dependent immunosuppression in cancer. Cancer Res. 2011;71:5393–9. The paper describes how the immune system can induce immune resistance responses by tissues in the local environment of immune reactions. CrossRefPubMed

82.

Della Chiesa M, Pesce S, Muccio L, Carlomagno S, Sivori S, Moretta A, et al. Features of memory-like and PD-1⁺ human NK cell subsets. Front Immunol. 2016;7:351–9. doi:10.3389/fimmu.2016.00351.CrossRefPubMedPubMedCentral

83.

Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumora T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.CrossRefPubMed

84.

Webster WS, Lohse CM, Thompson RH, et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 2006;107:46053.CrossRef

85.

Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.CrossRefPubMed

86.

Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports and adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4:127ra37.CrossRefPubMedPubMedCentral

87.

• Kumar V, Patel S, Tcyganov E, Gabrilovich D. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–20. The review describes the roles of myeloid-derived suppressor cells and their various local functions to suppress an ongoing immune reaction. CrossRefPubMedPubMedCentral

Titel: Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics
verfasst von: Jonathan L. Messerschmidt
Prianka Bhattacharya
Gerald L. Messerschmidt
Publikationsdatum: 01.10.2017
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 10/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-017-0625-2

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics